GLP 1 and Tirzepatide Therapy

Tirzepatide Therapy - Understanding appetite signals, benefits, side effects and safe prescribing

Clinical review: September 2026

The question is rarely simply, “Can this medicine help me lose weight?” More often it is, “Can it help me feel less at war with hunger, glucose or my health - and what does it ask of me in return?” GLP-1 medicines and tirzepatide deserve an answer that is neither sales pitch nor scolding.

Gut signals with a wider conversation

GLP-1 is a hormone released after eating. It influences appetite, slows stomach emptying and supports insulin release when glucose is high. Medicines that mimic GLP-1 can reduce appetite and improve glucose control. Tirzepatide acts on both GLP-1 and GIP pathways. These are not willpower injections; they alter biological signals involved in hunger, fullness and glucose regulation.

Benefit is real but individual

In clinical trials, semaglutide and tirzepatide therapy produced substantial average weight loss alongside lifestyle support in selected adults, and can improve glucose control in type 2 diabetes. Averages are not guarantees. Response, tolerability, access, food intake, activity, muscle preservation and the weight trajectory after stopping all vary. The important outcome is not a particular number on a scale but whether treatment is delivering meaningful health benefit without unacceptable burden.

Choosing carefully

Suitability depends on weight-related health, diabetes, medicines, kidney and liver health, pregnancy plans, previous pancreatitis or gallbladder disease, digestive symptoms and relevant personal or family endocrine tumour history. They are not used in pregnancy, and pregnancy planning needs a specific discussion because treatment should be stopped in advance. Tirzepatide can reduce the reliability of oral contraception during initiation and dose increases, so contraception advice must be individualised.

Side effects that deserve plain language

Nausea, constipation, diarrhoea, reflux and reduced appetite are common, especially while the dose is being increased. Slow dose escalation and attention to fluids, protein and regular meals can help, but not every side effect should be pushed through. Severe, persistent abdominal pain - particularly with vomiting - needs urgent medical assessment because acute pancreatitis is a recognised, rare but serious risk. Persistent vomiting or dehydration also needs prompt advice.

A treatment plan, not a prescription in isolation

Follow-up should include symptoms, nutrition, weight and waist trends where useful, blood pressure, glucose and relevant blood tests. It should also discuss what happens if benefit is limited, side effects dominate, or treatment is stopped. Long-term management includes keeping muscle, sleep, food quality, activity, mental wellbeing and cardiovascular risk in the picture. The medicine may change the volume of appetite; it cannot compose the whole orchestra.

Important safety note

Seek urgent assessment for severe or persistent abdominal pain, repeated vomiting, dehydration, or symptoms of gallbladder disease. Do not use these medicines in pregnancy. Discuss procedures, fasting, contraception and any new severe gastrointestinal symptoms with the prescribing team. This article cannot establish whether a medicine is suitable for an individual.